Polydextrose and GOS Blend for Infant Formula SCFA Profile
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prebiotics used in infant formulas do not replicate the short-chain fatty acid (SCFA) profile of breast milk, leading to potential gastrointestinal issues such as excess gas, bloating, and diarrhea, while also failing to effectively promote beneficial bacteria like Bifidobacteria.
Innovation Solution
Incorporating polydextrose (PDX) and galacto-oligosaccharides (GOS) into infant formulas at specific concentrations to simulate the functional attributes of human milk oligosaccharides, thereby increasing beneficial bacteria and optimizing the SCFA profile to resemble that of breast-fed infants, while reducing fermentation rates and gas production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional prebiotics are used in infant formulas, then beneficial bacteria growth is promoted, but gastrointestinal discomfort (gas, bloating, diarrhea) increases
Solution Approach 1:
The patent changes the chemical composition parameters by using a specific blend of polydextrose (7.5-15 g/L) and galacto-oligosaccharide (2.5-7.5 g/L) in defined ratios, which alters the fermentation characteristics to reduce gas production while maintaining beneficial bacteria promotion
Solution Approach 2:
The patent combines polydextrose and galacto-oligosaccharide in specific proportions to create a composite prebiotic system that leverages the complementary properties of both ingredients: polydextrose for low gas production and GOS for selective Bifidobacteria growth stimulation
2Reliability
If human milk oligosaccharides are replicated in formula, then SCFA profile similar to breast milk is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent creates a simplified copy of human milk oligosaccharide functionality by using polydextrose and GOS blends that replicate the key metabolic outcome (SCFA profile) without attempting to reproduce the complex structure of HMOS
Solution Approach 2:
The patent adjusts the concentration parameters of polydextrose and GOS to achieve target SCFA profiles (acetate, propionate, butyrate ratios) that match breast milk-fed infants, simplifying the manufacturing process compared to producing actual HMOS
3Reliability
If fermentation rate is increased to promote bacteria growth, then beneficial bacteria population increases, but gas production increases
Solution Approach 1:
The patent modifies the fermentation parameters by selecting prebiotics with different fermentation rates: polydextrose ferments slowly producing minimal gas, while GOS ferments at a moderate rate supporting Bifidobacteria growth with acceptable gas levels
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PDX and GOS effectively increase beneficial bacteria, optimize the SCFA profile, and reduce gastrointestinal discomfort in formula-fed infants, mimicking the benefits of breast milk oligosaccharides without causing adverse effects like bloating or diarrhea.
Implementation Method 1
These oligosaccharides are resistant to enzymatic digestion in the upper gastrointestinal tract and reach the colon intact, where they serve as substrates for colonic fermentation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is directed to a novel use of PDX in the manufacture of a medicament for increasing the production of acetate, decreasing the production of butyrate, increasing the population and species of beneficial bacteria and slowing the rate of fermentation of prebiotics within the gut of a formula-fed infant.